Journal of Molecular and Cellular Cardiology
Volume 50, Issue 5 , Pages 777-784 , May 2011

S100A1 gene therapy for heart failure: A novel strategy on the verge of clinical trials

  • David Rohde

      Affiliations

    • Laboratory for Molecular and Translational Cardiology, Center for Molecular and Translational Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
    • These authors contributed equally.
    • ,
  • Henriette Brinks

      Affiliations

    • Department of Cardiac and Vascular Surgery, Inselspital University Hospital Bern, Bern, Switzerland
    • These authors contributed equally.
    • ,
  • Julia Ritterhoff

      Affiliations

    • Laboratory for Molecular and Translational Cardiology, Center for Molecular and Translational Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
    • ,
  • Gang Qui

      Affiliations

    • Laboratory for Cardiac Stem Cell & Gene Therapy, Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, 19107, USA
    • ,
  • Shumei Ren

      Affiliations

    • Laboratory for Cardiac Stem Cell & Gene Therapy, Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, 19107, USA
    • ,
  • Patrick Most

      Affiliations

    • Laboratory for Molecular and Translational Cardiology, Center for Molecular and Translational Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany
    • Laboratory for Cardiac Stem Cell & Gene Therapy, Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, 19107, USA
    • Corresponding Author InformationCorresponding author. Center for Molecular and Translational Cardiology, Department of Internal Medicine III, University of Heidelberg, 69120 Heidelberg, Germany. Tel.: +49 (0)6221 568900

Received 10 June 2010 ,Revised 11 August 2010 ,Accepted 13 August 2010.

References 

  1. AHA . Heart disease and stroke statistics — 2010 update. Circulation. 2010;121:e1–e170
  2. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45–79
  3. Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res. 2008;102(12):1458–1470
  4. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol. 2008;70:23–49
  5. Houser SR, Margulies KB. Is depressed myocyte contractility centrally involved in heart failure?. Circ Res. 2003;92(4):350–358
  6. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res. 2000;86(6):616–621
  7. Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14(5):355–367
  8. Kraus C, Rohde D, Weidenhammer C, Qiu G, Pleger ST, Voelkers M, et al. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol. 2009;47(4):445–455
  9. Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol. 2007;293(2):R568–R577
  10. Voelkers M, Rohde D, Goodman C, Most P. S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function. J Biomed Biotechnol. 2010;178614
  11. Most P, Koch WJ. S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy. Future Cardiol. 2007;3:5–11
  12. Wright NT, Cannon BR, Zimmer DB, Weber DJ. S100A1: structure, function, and therapeutic potential. Curr Chem Biol. 2009;3(2):138–145
  13. Remppis A, Greten T, Schafer BW, Hunziker P, Erne P, Katus HA, et al. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta. 1996;1313(3):253–257
  14. Desjardins JF, Pourdjabbar A, Quan A, Leong-Poi H, Teichert-Kuliszewska K, Verma S, et al. Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction. Am J Physiol Heart Circ Physiol. 2009;296(5):H1457–H1465
  15. Most P, Pleger ST, Völkers M, Heidt B, Boerries M, Weichenhan D, et al. Cardiac adenoviral S100A1 gene transfer rescues failing myocardium. J Clin Investig. 2004;114:1550–1563
  16. Most P, Seifert H, Gao E, Funakoshi H, Volkers M, Heierhorst J, et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation. 2006;114(12):1258–1268
  17. Tsoporis JN, Marks A, Zimmer DB, McMahon C, Parker TG. The myocardial protein S100A1 plays a role in the maintenance of normal gene expression in the adult heart. Mol Cell Biochem. 2003;242(1–2):27–33
  18. Gupta RC, Mishra S, Rastogi S, Wang M, Rousso B, Mika Y, et al. Ca(2+)-binding proteins in dogs with heart failure: effects of cardiac contractility modulation electrical signals. Clin Transl Sci. 2009;2(3):211–215
  19. Pleger ST, Shan C, Kziencek J, Mueller O, Bekereddjian R, Remppis A, et al. Retroinfusion-facilitated inotropic AAV9-S100A1 gene therapy restores global cardiac function in a clinically relevant pig heart failure model. Circulation. 2008;118:S_792
  20. Kiewitz R, Lyons GE, Schafer BW, Heizmann CW. Transcriptional regulation of S100A1 and expression during mouse heart development. Biochim Biophys Acta. 2000;1498(2–3):207–219
  21. Boerries M, Most P, Gledhill JR, Walker JE, Katus HA, Koch WJ, et al. Ca2+-dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol. 2007;27(12):4365–4373
  22. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Borries M, et al. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci USA. 2001;98(24):13889–13894
  23. Most P, Eicher C, Börries M, Schweda C, Völkers M, Wedel T, et al. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci. 2005;118:421–431
  24. Remppis A, Most P, Löffler E, Ehlermann P, Bernotat J, Pleger ST, et al. The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol. 2002;97(Suppl.1):I/56–I/62
  25. Remppis A, Pleger ST, Most P, Lindenkamp J, Ehlermann P, Löffler E, et al. S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med. 2004;6:387–394
  26. Most P, Remppis A, Pleger ST, Löffler E, Ehlermann P, Bernotat J, et al. Transgenic overexpression of the Ca2+ binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem. 2003;278(5):33809–33817
  27. Volkers M, Loughrey CM, Macquaide N, Remppis A, DeGeorge BR, Wegner FV, et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium. 2007;41(2):135–143
  28. Voelkers M, Weidenhammer C, Herzog N, Friedrich O, Fink RHA, Koch WJ, et al. S100A1 prevents arrythmogenic diastolic sarcoplasmic reticulum calcium leak in ventricular cardiomyocytes. Circulation. 2008;118:S_527
  29. Kettlewell S, Most P, Currie S, Koch H, Smith GL. S100A1 increases the gain of excitation— coupling in isolated rabbit ventricular cardiomyocytes. J Mol Cell Cardiol. 2005;39:900–910
  30. Most P, Remppis A, Weber C, Bernotat J, Ehlermann P, Pleger ST, et al. The C-terminus (aa 75–94) and the linker region (aa 42–54) of the Ca2+ binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibres. J Biol Chem. 2003;278(29):26356–26364
  31. Treves S, Scutari E, Robert M, Groh S, Ottolia M, Prestipino G, et al. Interaction of S100A1 with the Ca2+ release channel (ryanodine receptor) of skeletal muscle. Biochemistry. 1997;36(38):11496–11503
  32. Wright NT, Prosser BL, Varney KM, Zimmer DB, Schneider MF, Weber DJ. S100A1 and calmodulin compete for the same binding site on ryanodine receptor. J Biol Chem. 2008;283(39):26676–26683
  33. Kiewitz R, Acklin C, Schafer BW, Maco B, Uhri KB, Wuytack F, et al. Ca(2+)-dependent interaction of S100A1 with the sarcoplasmic reticulum Ca(2+)-ATPase2a and phospholamban in the human heart. Biochem Biophys Res Commun. 2003;306(2):550–557
  34. Wright NT, Varney KM, Karen CE, Markowitz J, Rossitza KG, Zimmer DB, et al. The three-dimensional solution structure of Ca2+-bound S100A1 as determined by NMR spectroscopy. J Mol Biol. 2005;353:410–426
  35. Yamasaki R, Berri M, Wu Y, Trombitas K, McNabb M, Kellermayer MS, et al. Titin–actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/s100a1. Biophys J. 2001;81(4):2297–2313
  36. Fukushima H, Chung C, Granzier H. Titin-isoform dependence of titin–actin interaction and its regulation by S100A1/Ca2+ in skinned myocardium. J Biomed Biotechnol. 2010;2010:727239 [published online].
  37. LeWinter MM, Granzier H. Cardiac titin: a multifunctional giant. Circulation. 2010;121(19):2137–2145
  38. Maco B, Mandinova A, Durrenberger MB, Schafer BW, Uhrik KB, Heizmann CW. Ultrastructural distribution of the S100A1 Ca2+-binding protein in the human heart. Physiol Res. 2001;50:567–574
  39. Most P, Zeitz O, Janssen PML, Ehlermann P, Reppel M, Hasenfuss G, et al. S100A1 modulates Ca2+ sensitivity of cardiac myofilaments. Eur Heart J. 2000;21:60;Suppl.
  40. Brezova A, Heizmann CW, Uhrik B. Immunocytochemical localization of S100A1 in mitochondria on cryosections of the rat heart. Gen Physiol Biophys. 2007;26(2):143–149
  41. Ackermann GE, Domenighetti AA, Deten A, Bonath I, Marenholz I, Pedrazzini T, et al. S100A1 deficiency results in prolonged ventricular repolarization in response to sympathetic activation. Gen Physiol Biophys. 2008;27(2):127–142
  42. Du XJ, Cole TJ, Tenis N, Gao XM, Kontgen F, Kemp BE, et al. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biol. 2002;22(8):2821–2829
  43. Gusev K, Ackermann GE, Heizmann CW, Niggli E. Ca(2+) signaling in mouse cardiomyocytes with ablated S100A1 protein. Gen Physiol Biophys. 2009;28(4):371–383
  44. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007;115(19):2506–2515
  45. Pleger ST, Most P, Heidt B, Voelkers M, Hata JA, Katus HA, et al. S100A1 gene transfer in myocardium. Eur J Med Res. 2006;11(10):418–422
  46. Pleger ST, Remppis A, Heidt B, Völkers M, Chaprun JK, Kuhn M, et al. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther. 2005;12:1120–1129
  47. Rudy Y, Ackerman MJ, Bers DM, Clancy CE, Houser SR, London B, et al. Systems approach to understanding electromechanical activity in the human heart: a national heart, lung, and blood institute workshop summary. Circulation. 2008;118(11):1202–1211
  48. Dixon JA, Spinale FG. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail. 2009;2(3):262–271
  49. Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Gutkind JS, Chiorini JA. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med. 2010;16:662–664

PII: S0022-2828(10)00299-3

doi: 10.1016/j.yjmcc.2010.08.012

Journal of Molecular and Cellular Cardiology
Volume 50, Issue 5 , Pages 777-784 , May 2011

Article Tools

* Image Usage & Resolution